Istradefylline (Nourianz)
Introduction
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Istradefylline (Nourianz)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Istradefylline (Nourianz)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Istradefylline (Nourianz) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Istradefylline (brand name Nourianz; development code KW-6002) is an oral adenosine A2A receptor antagonist developed by Kyowa Kirin for the treatment of "off" episodes in adults with [Parkinson's disease](/diseases/parkinsons-disease) receiving [levodopa](/therapeutics/levodopa)/carbidopa. It is the first non-dopaminergic drug approved by the FDA for [Parkinson's disease](/diseases/parkinsons-disease) in over two decades and represents the first clinical application of adenosine receptor pharmacology in [neurodegeneration](/diseases).[@mller2020] [@kondo2015]
The FDA approved istradefylline on August 27, 2019, as an add-on treatment to [levodopa](/therapeutics/levodopa)/carbidopa in PD patients experiencing "off" episodes — periods when PD medication is not working optimally and motor symptoms return. Istradefylline had been approved in Japan since 2013, where it was the first adenosine A2A antagonist to reach the market for any indication.[@kondo2015] [@schiffmann2007]
...Istradefylline (Nourianz)
Introduction
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Istradefylline (Nourianz)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Istradefylline (Nourianz)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Istradefylline (Nourianz) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Istradefylline (brand name Nourianz; development code KW-6002) is an oral adenosine A2A receptor antagonist developed by Kyowa Kirin for the treatment of "off" episodes in adults with [Parkinson's disease](/diseases/parkinsons-disease) receiving [levodopa](/therapeutics/levodopa)/carbidopa. It is the first non-dopaminergic drug approved by the FDA for [Parkinson's disease](/diseases/parkinsons-disease) in over two decades and represents the first clinical application of adenosine receptor pharmacology in [neurodegeneration](/diseases).[@mller2020] [@kondo2015]
The FDA approved istradefylline on August 27, 2019, as an add-on treatment to [levodopa](/therapeutics/levodopa)/carbidopa in PD patients experiencing "off" episodes — periods when PD medication is not working optimally and motor symptoms return. Istradefylline had been approved in Japan since 2013, where it was the first adenosine A2A antagonist to reach the market for any indication.[@kondo2015] [@schiffmann2007]
Mechanism of Action
Adenosine A2A Receptors in the Basal Ganglia
The mechanism of istradefylline is distinct from all other approved PD therapies because it acts on the adenosinergic system rather than the dopaminergic system. Understanding its mechanism requires knowledge of [basal ganglia](/brain-regions/basal-ganglia) circuit physiology: [@schwarzschild2006]
In the striatum, medium spiny [neurons](/entities/neurons) (MSNs) of the indirect pathway co-express dopamine D2 receptors and adenosine A2A receptors. Under normal conditions, dopamine binding to D2 receptors on these [medium spiny neurons](/cell-types/medium-spiny-neurons) inhibits the indirect pathway, facilitating movement. Adenosine, acting at A2A receptors on the same [neurons](/entities/neurons), has the opposite effect — it excites the indirect pathway and thereby suppresses movement.[@schiffmann2007] [@jenner2021]
In [Parkinson's disease](/diseases/parkinsons-disease), the loss of [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta reduces dopaminergic input to the striatum. This causes: [@fuxe2007]
Reduced D2 receptor stimulation on indirect pathway MSNs
Relative overactivity of adenosine A2A signaling (which is no longer counterbalanced by dopamine)
Excessive activation of the indirect pathway, leading to increased inhibitory output from the globus pallidus internus/[subthalamic nucleus](/cell-types/subthalamic-nucleus) circuit
Motor impairment: bradykinesia, rigidity, and the "off" state[@schwarzschild2006]A2A Receptor Antagonism
Istradefylline blocks A2A receptors selectively (Ki = 2.2 nM for A2A vs. >1000 nM for A1 receptors), releasing the indirect pathway from the excitatory influence of adenosine. This: [@nourianz2019]
- Restores the balance between the direct and indirect pathways
- Reduces excessive GABAergic output from the indirect pathway
- Improves motor function without directly increasing dopaminergic activity
- Provides a complementary mechanism to [levodopa](/therapeutics/levodopa) therapy[@jenner2021]
The non-dopaminergic nature of this mechanism is therapeutically significant because it reduces "off" time without amplifying the peak-dose complications (dyskinesias, hallucinations) associated with increasing dopaminergic stimulation. [@barajimenez2003]
Interaction with Dopaminergic Signaling
At the intracellular level, A2A and D2 receptors form functional heteromers on [medium spiny neurons](/cell-types/medium-spiny-neurons). Adenosine A2A stimulation allosterically reduces D2 receptor affinity for dopamine and opposes D2-mediated intracellular signaling (via opposing effects on adenylyl cyclase and cAMP). By blocking A2A, istradefylline enhances the functional efficacy of dopamine at D2 receptors, synergizing with exogenous dopamine from [levodopa](/therapeutics/levodopa) therapy.[@fuxe2007] [@nourianz]
Pharmacology
Pharmacokinetics
- Absorption: Rapidly absorbed orally; peak plasma concentration in 1–4 hours. High-fat meals increase exposure by approximately 20% but do not alter efficacy
- Distribution: High protein binding (98%); volume of distribution ~44 L
- Metabolism: Primarily metabolized by CYP3A4 and CYP1A1/1A2. Major metabolite M1 is inactive
- Half-life: Terminal elimination half-life of approximately 46–83 hours, supporting once-daily dosing
- Excretion: Primarily eliminated via hepatic metabolism; renal excretion of unchanged drug is <1%[@nourianz2019]
Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase istradefylline exposure; maximum dose should not exceed 20 mg/day
- CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease istradefylline exposure; may reduce efficacy
- Tobacco smoking: Induces CYP1A1/1A2 and may decrease istradefylline levels
- No clinically significant interactions with [levodopa](/therapeutics/levodopa)/carbidopa, dopamine agonists, or [MAO-B inhibitors](/therapeutics/mao-b-inhibitors)[@nourianz2019]
Dosing
- Recommended starting dose: 20 mg once daily as adjunctive therapy to [levodopa](/therapeutics/levodopa)/carbidopa
- Maximum dose: 40 mg once daily
- Hepatic impairment: Maximum 20 mg/day in moderate hepatic impairment (Child-Pugh B); not recommended in severe impairment
- Available as film-coated tablets (20 mg and 40 mg)[@nourianz2019]
Clinical Trials
Pivotal Trials
Istradefylline was evaluated in four randomized, double-blind, placebo-controlled Phase III trials enrolling a total of 1,143 participants with [Parkinson's disease](/diseases/parkinsons-disease) experiencing ≥2 hours of "off" time daily while on stable [levodopa](/therapeutics/levodopa)/carbidopa therapy (disease duration average ~9 years).[@mller2020] [@lewitt2020]
Study 6002-US-013 (N=231): [@ascherio2001]
- Istradefylline 40 mg/day vs. placebo
- Primary endpoint: Percentage change from baseline in "off" time
- Result: −10.8% (istradefylline) vs. −4.0% (placebo); p=0.03
- Corresponding to −1.8 hours vs. −0.6 hours reduction in daily "off" time
Study 6002-US-018 (N=395):
- Istradefylline 20 mg and 40 mg vs. placebo
- Both doses demonstrated significant reductions in "off" time vs. placebo
Study 6002-009 (Japan, N=373) and
Study 6002-US-006 (N=196):
- Consistent direction of effect, with the Japanese study showing robust efficacy
Pooled analysis: Across trials, istradefylline 20–40 mg reduced daily "off" time by approximately 0.7–1.2 hours more than placebo, with corresponding increases in "on" time without troublesome dyskinesia.[@mller2020]
Long-term Safety
An open-label 52-week extension study demonstrated sustained "off" time reduction and acceptable tolerability with chronic dosing. No evidence of tachyphylaxis or loss of efficacy was observed over the treatment period.[@barajimenez2003]
Safety Profile
Common Adverse Events
In clinical trials, the most frequently reported adverse events were:
- Dyskinesia (17–18% vs. 8% placebo) — may reflect improved [levodopa](/therapeutics/levodopa) efficacy rather than direct toxicity
- Dizziness (3%)
- Constipation (4%)
- Nausea (3%)
- Hallucinations (1–3%)
- Insomnia (2%)
Important Safety Considerations
- Dyskinesia management: If troublesome dyskinesia occurs, reduction of [levodopa](/therapeutics/levodopa) dose may be warranted
- Impulse control disorders: Reported in postmarketing experience, as with other PD medications
- Psychiatric symptoms: Hallucinations and psychotic behavior, particularly in elderly patients
- Hepatic: Not recommended in severe hepatic impairment
- Pregnancy: Category C; not studied in pregnant women[@nourianz]
Treatment discontinuation due to adverse effects was similar between istradefylline (5–6%) and placebo (5%), indicating good overall tolerability.
Clinical Context
Addressing a Therapeutic Gap
In the current PD treatment paradigm, all approved therapies until istradefylline worked by modulating the dopaminergic system — [levodopa](/therapeutics/levodopa), [dopamine agonists](/therapeutics/dopamine-agonists), [MAO-B inhibitors](/therapeutics/mao-b-inhibitors), and [COMT inhibitors](/therapeutics/comt-inhibitors). As [Parkinson's disease](/diseases/parkinsons-disease) progresses, motor fluctuations (wearing-off, "off" episodes) become increasingly difficult to manage with dopaminergic optimization alone. Istradefylline provides a non-dopaminergic mechanism to reduce "off" time, particularly valuable when:
- Increasing [levodopa](/therapeutics/levodopa) dose causes unacceptable dyskinesia or psychiatric side effects
- [Dopamine agonists](/therapeutics/dopamine-agonists) are not tolerated (especially in elderly patients)
- Patients remain with significant "off" time despite optimized dopaminergic therapy[@lewitt2020]
Positioning in Treatment Algorithm
Istradefylline is currently indicated only as adjunctive therapy — not as monotherapy. It is typically added to [levodopa](/therapeutics/levodopa)/carbidopa regimens in patients with motor fluctuations. Guidelines from the American Academy of Neurology and the Movement Disorder Society include istradefylline as an option for managing motor fluctuations, though long-term comparative studies with other adjunctive therapies are limited.
Future Adenosine A2A Research
The approval of istradefylline has stimulated research into other A2A receptor-based approaches:
- Potential cognitive benefits: Preclinical evidence suggests A2A antagonism may have neuroprotective and pro-cognitive effects beyond motor symptom relief
- Application in other neurodegenerative diseases: A2A antagonism is being investigated for potential benefits in [Alzheimer's disease](/diseases/alzheimers-disease) (where adenosine signaling is dysregulated), [Huntington's disease](/mechanisms/huntington-pathway), and [ALS](/diseases/amyotrophic-lateral-sclerosis)
- Caffeine connection: Epidemiological data showing reduced PD risk with caffeine consumption (a non-selective adenosine receptor antagonist) provided the original rationale for developing selective A2A antagonists[@ascherio2001]
See Also
- [Medium Spiny Neurons (MSNs)](/cell-types/medium-spiny-neurons)
- [COMT Inhibitors](/therapeutics/comt-inhibitors)
- [Dopamine Agonists in Parkinson's Disease](/therapeutics/dopamine-agonists)
- [Levodopa](/therapeutics/levodopa)
- [MAO-B Inhibitors](/therapeutics/mao-b-inhibitors)
External Links
- [ClinicalTrials.gov — Istradefylline studies](https://clinicaltrials.gov/search?intr=istradefylline)
- [Nourianz HCP site](https://www.nourianzhcp.com/)
- [FDA Label — Nourianz](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf)
Background
The study of Istradefylline (Nourianz) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
[Müller et al., The Belated US FDA Approval of the Adenosine A2A Receptor Antagonist Istradefylline for Treatment of Parkinson's Disease, Purinergic Signalling 2020 (2020)](https://doi.org/10.1007/s11302-020-09694-2)
[Unknown, Kondo & Mizuno, A Long-Term Study of Istradefylline Safety and Efficacy in PD, Clinical Neuropharmacology 2015 (2015)](https://doi.org/10.1097/WNF.0000000000000073)
[Schiffmann et al., Adenosine A2A Receptors and Basal Ganglia Physiology, Progress in Neurobiology 2007 (2007)](https://doi.org/10.1016/j.pneurobio.2007.05.001)
[Schwarzschild et al., Targeting Adenosine A2A Receptors in Parkinson's Disease, Trends in Neurosciences 2006 (2006)](https://doi.org/10.1016/j.tins.2006.09.004)
[Jenner et al., Istradefylline — A First Generation Adenosine A2A Antagonist for PD, Expert Review of Neurotherapeutics 2021 (2021)](https://doi.org/10.1080/14737175.2021.1880896)
[Fuxe et al., Adenosine A2A–Dopamine D2 Receptor–Receptor Heteromeric Interactions, Biochimica et Biophysica Acta 2007 (2007)](https://doi.org/10.1016/j.bbamem.2006.09.005)
Unknown, Nourianz Prescribing Information, Kyowa Kirin (2019)
[Bara-Jimenez et al., Adenosine A2A Receptor Antagonist Treatment of Parkinson's Disease, Neurology 2003 (2003)](https://doi.org/10.1212/01.WNL.0000073152.14867.83)
Unknown, Nourianz Safety Profile — Kyowa Kirin (n.d.)
[LeWitt et al., Istradefylline to Treat OFF Episodes in PD, Neurology Clinical Practice 2020 (2020)](https://doi.org/10.1212/CPJ.0000000000000811)
[Ascherio et al., Prospective Study of Caffeine Consumption and Risk of PD, Annals of Neurology 2001 (2001)](https://doi.org/10.1002/ana.1052)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ADORA2A
Related Analyses:
- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄